CD4 and hepatocellular carcinoma: For example, the newly identified CD4 + CXCL13 + BHLHe40 + Th1-like CD4 + subset might explain the difference in responses to anti-PD1 therapy in patients with colorectal cancer presenting with MSI and MSS, while PD-1high CD4 + CD8 + T cells are associated with prolonged survival in patients with HCC [141–143].